Skip to main content
Journal cover image

An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.

Publication ,  Journal Article
Julander, JG; Demarest, JF; Taylor, R; Gowen, BB; Walling, DM; Mathis, A; Babu, YS
Published in: Antiviral Res
November 2021

Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Antiviral Res

DOI

EISSN

1872-9096

Publication Date

November 2021

Volume

195

Start / End Page

105180

Location

Netherlands

Related Subject Headings

  • Virology
  • SARS-CoV-2
  • Pyrrolidines
  • Nucleosides
  • Marburgvirus
  • Drug Evaluation, Preclinical
  • Clinical Trials, Phase I as Topic
  • Antiviral Agents
  • Animals
  • Adenosine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Julander, J. G., Demarest, J. F., Taylor, R., Gowen, B. B., Walling, D. M., Mathis, A., & Babu, Y. S. (2021). An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antiviral Res, 195, 105180. https://doi.org/10.1016/j.antiviral.2021.105180
Julander, Justin G., James F. Demarest, Ray Taylor, Brian B. Gowen, Dennis M. Walling, Amanda Mathis, and Y. S. Babu. “An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.Antiviral Res 195 (November 2021): 105180. https://doi.org/10.1016/j.antiviral.2021.105180.
Julander JG, Demarest JF, Taylor R, Gowen BB, Walling DM, Mathis A, et al. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antiviral Res. 2021 Nov;195:105180.
Julander, Justin G., et al. “An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.Antiviral Res, vol. 195, Nov. 2021, p. 105180. Pubmed, doi:10.1016/j.antiviral.2021.105180.
Julander JG, Demarest JF, Taylor R, Gowen BB, Walling DM, Mathis A, Babu YS. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antiviral Res. 2021 Nov;195:105180.
Journal cover image

Published In

Antiviral Res

DOI

EISSN

1872-9096

Publication Date

November 2021

Volume

195

Start / End Page

105180

Location

Netherlands

Related Subject Headings

  • Virology
  • SARS-CoV-2
  • Pyrrolidines
  • Nucleosides
  • Marburgvirus
  • Drug Evaluation, Preclinical
  • Clinical Trials, Phase I as Topic
  • Antiviral Agents
  • Animals
  • Adenosine